

Billy White abstract

There are limited evidence-based interventions currently available for children and young people with type 2 diabetes. NICE currently only recommends metformin and lifestyle change in this group yet clearly this is insufficient for this aggressive disease.

Billy will cover mainstream therapeutic agents used in adults including SGLT-2 inhibitors, and GLP1 agonists and will argue that they should be more widely used in those under 18 years of age. Furthermore, Billy will argue that clinicians should consider bariatric surgery as an effective intervention to control not only type 2 diabetes but also co-morbidities such as NALFD, PCOS and sleep apnoea.